Enterprise Value

1.563B

Cash

832.8M

Avg Qtr Burn

-3.047M

Short % of Float

12.86%

Insider Ownership

9.61%

Institutional Own.

86.80%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KIMMTRAK (Tebentafusp) (gp100) Details
Metastatic uveal melanoma, Melanoma, Cancer

Approved

Quarterly sales

Phase 3

Data readout

Phase 3

Data readout

KIMMTRAK (Tebentafusp) (gp100) Details
Cancer, Melanoma, Metastatic uveal melanoma

Phase 3

Initiation

IMC-F106C (Brenetafusp) Details
Breast cancer, Solid tumor/s, Ovarian cancer, Endometrial cancer, Cancer

Phase 1/2

Data readout

Phase 1/2

Update

IMC-C103C Details
Ovarian cancer, Head and neck cancer, Cancer, Non-small cell lung carcinoma, Gastric cancer, Solid tumor/s

Phase 1

Data readout

IMC-I109V Details
Viral infection, Hepatocellular carcinoma, Hepatitis B

Phase 1

Data readout

IMC-M113V Details
Human immunodeficiency virus, Viral infection

Phase 1

Data readout